Browse by author
Lookup NU author(s): Dr Stephen Ball
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Conventional insulin therapy is an imperfect treatment for diabetes mellitus, often failing to match insulin with prevailing blood glucose concentration. Accordingly, there is a drive for approaches such as β-cell replacement therapy, which is a permanent replacement for the lack of endogenous insulin production. The lack of cadaveric islets for transplantation determines that researchers must explore alternative sources of graft material. Cell engineering of non-β cells and selective expansion of stem cells are key potential sources. The past decade has witnessed an increase in our understanding of the molecular basis of pancreas and β-cell development. Our understanding of the molecular blueprint of how a β cell is made and maintained is crucial to realizing the potential of cell engineering and stem cell technologies in this area. This review outlines progress in this exciting field and high-lights the key role of development in guiding our appraisal of these new technologies.
Author(s): Ball SG, Barber TM
Publication type: Review
Publication status: Published
Journal: Trends in Endocrinology and Metabolism
Year: 2003
Volume: 14
Issue: 8
Pages: 349-355
Print publication date: 01/10/2003
ISSN (print): 1043-2760
ISSN (electronic): 1879-3061
URL: http://dx.doi.org/10.1016/S1043-2760(03)00105-X
DOI: 10.1016/S1043-2760(03)00105-X
PubMed id: 14516932
